Zdrowie i gospodarka · 06/05/2015
FDA Releases Draft Guidance on Bioequivalence for Clozapine Orally Disintegrating Tablets
The FDA has made available a draft guidance document outlining recommendations for bioequivalence studies to support the approval of clozapine orally disintegrating tablets, a key step in the process for generic manufacturers.
Source: Federal Register — Food and Drug AdministrationOpen original release →